Growth & profitability
- Revenue has grown 17.5% per year over the past 5 years.
LEXX Financials Lexaria Bioscience Corp.
14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $705923 | -$12M | 99.6% | -1683.0% | -$10M | — | — |
| 2024 | $464278 | -$6M | 99.0% | -1239.2% | -$5M | — | — |
| 2023 | $226208 | -$7M | 86.1% | -2888.5% | -$6M | — | — |
| 2022 | $255397 | -$7M | 71.9% | -2591.7% | -$5M | — | $6M |
| 2021 | $722738 | -$4M | 75.7% | -786.8% | — | — | $11M |
| 2020 | $314793 | -$4M | 68.4% | 0.0% | -$3M | — | $1M |
| 2019 | — | $4M | — | — | -$4M | — | $1M |
| 2018 | — | $7M | — | — | — | — | $2M |
| 2017 | — | -$2M | — | — | -$2M | — | $3M |
| 2016 | — | -$1M | — | — | -$663950 | — | $93409 |
| 2015 | — | -$2M | — | — | -$2M | — | $260075 |
| 2014 | — | -$2M | — | — | — | — | $703030 |
| 2011 | — | -$538226 | — | — | — | — | $31201 |
| 2010 | — | -$552462 | — | — | — | — | $62989 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Feb '26 | $20000 | -$1M | 100.0% | -7259.5% | -$2M | — | $5M |
| Nov '25 | $0 | -$2M | — | — | -$984098 | — | $4M |
| Aug '25 | $174000 | -$3M | 100.0% | -1545.2% | -$3M | — | — |
| May '25 | $174000 | -$4M | 100.0% | -2155.4% | -$4M | — | $5M |
| Feb '25 | $174000 | -$3M | 100.0% | -1581.0% | -$1M | — | $7M |
| Nov '24 | $183923 | -$3M | 98.5% | -1463.0% | -$3M | — | — |
| Aug '24 | $84000 | -$2M | 100.0% | -2622.7% | -$2M | — | — |
| May '24 | $84000 | -$2M | 100.0% | -2074.9% | -$1M | — | — |
| Feb '24 | $145000 | -$649539 | 100.0% | -460.7% | -$619614 | — | — |
| Nov '23 | $151278 | -$1M | 96.8% | -753.0% | -$1M | — | — |
| Aug '23 | $30741 | -$1M | 100.0% | -3624.2% | -$2M | — | — |
| May '23 | $77707 | -$2M | 83.6% | -3089.6% | -$2M | — | — |
| Feb '23 | $20025 | -$1M | 85.2% | -6609.9% | -$1M | — | $3M |
| Nov '22 | $101476 | -$2M | 84.4% | -1670.8% | -$1M | — | $5M |
| Aug '22 | $111150 | -$1M | 62.9% | -1361.4% | -$1M | — | $6M |
| May '22 | $99717 | -$2M | 81.3% | -2425.2% | -$1M | — | $7M |
| Feb '22 | $30650 | -$1M | 79.2% | 0.0% | -$1M | — | $8M |
| Nov '21 | $13880 | -$2M | 59.9% | 0.0% | -$1M | — | $10M |
| Aug '21 | $31021 | -$1M | 34.5% | -4199.3% | — | — | $11M |
| May '21 | $204055 | -$3M | 70.6% | -1257.8% | — | — | $8M |
Valuation over time
How the market has priced LEXX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 265.0× (Mar '23) to 19.7× (Jun '26).
P/S
Frequently asked questions
Is LEXX growing its revenue and profit?
Over the past 5 years, Lexaria Bioscience Corp.'s revenue has grown 17.5% per year. These are computed facts, not advice.
How much debt does LEXX have?
As of FY2025, Lexaria Bioscience Corp. reported — of total debt against — of cash.
What is LEXX's profit margin?
In FY2025, gross margin was 99.6%, operating margin -1683.0%, and net margin -1686.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.